PL2575865T3 - Kompozycja farmaceutyczna obejmująca AVE0010 i insulinę glargine - Google Patents

Kompozycja farmaceutyczna obejmująca AVE0010 i insulinę glargine

Info

Publication number: PL2575865T3
Authority: PL; Poland
Prior art keywords: ave0010; pharmaceutical composition; insulin glargine; glargine; insulin
Prior art date: 2010-05-28

Application number

PL11723919T

Other languages

English (en)

Inventor

Reinhard Becker

Gerrit Hauck

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-28

Filing date

2011-05-27

Publication date

2015-06-30

2011-05-27 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2015-06-30 Publication of PL2575865T3 publication Critical patent/PL2575865T3/pl

Links

108010057186 Insulin Glargine Proteins 0.000 title 1
COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 title 1
XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 title 1
229960002869 insulin glargine Drugs 0.000 title 1
229960001093 lixisenatide Drugs 0.000 title 1
108010004367 lixisenatide Proteins 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
Immunology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

PL11723919T 2010-05-28 2011-05-27 Kompozycja farmaceutyczna obejmująca AVE0010 i insulinę glargine PL2575865T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP10164368A EP2389945A1 (en)	2010-05-28	2010-05-28	Pharmaceutical composition comprising AVE0010 and insulin glargine
PCT/EP2011/058764 WO2011147980A1 (en)	2010-05-28	2011-05-27	Pharmaceutical composition comprising ave0010 and insulin glargine
EP11723919.4A EP2575865B1 (en)	2010-05-28	2011-05-27	Pharmaceutical Composition Comprising AVE0010 and Insulin Glargine

Publications (1)

Publication Number	Publication Date
PL2575865T3 true PL2575865T3 (pl)	2015-06-30

Family

ID=42773054

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11723919T PL2575865T3 (pl)	2010-05-28	2011-05-27	Kompozycja farmaceutyczna obejmująca AVE0010 i insulinę glargine

Country Status (9)

Country	Link
US (1)	US20130079279A1 (pl)
EP (4)	EP2389945A1 (pl)
AR (1)	AR081254A1 (pl)
DK (1)	DK2575865T3 (pl)
ES (1)	ES2532994T3 (pl)
HU (1)	HUE024486T2 (pl)
PL (1)	PL2575865T3 (pl)
TW (1)	TW201201832A (pl)
WO (1)	WO2011147980A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2371361T3 (es)	2005-12-28	2011-12-30	Novo Nordisk A/S	Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
JP4959005B2 (ja)	2008-10-30	2012-06-20	ノボ・ノルデイスク・エー／エス	毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
CN102596175A (zh)	2009-07-06	2012-07-18	赛诺菲-安万特德国有限公司	含有甲硫氨酸的水性胰岛素制备物
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
DK2632478T3 (da)	2010-10-27	2019-10-07	Novo Nordisk As	Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
DK2741765T3 (en)	2011-08-10	2016-06-13	Adocia	Injectable solution of at least one type of basal insulin
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9198971B2 (en)	2012-01-09	2015-12-01	Adocia	Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
FR3001896B1 (fr)	2013-02-12	2015-07-03	Adocia	Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
US20150314003A2 (en)	2012-08-09	2015-11-05	Adocia	Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001895B1 (fr)	2013-02-12	2015-07-03	Adocia	Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
TWI780236B (zh)	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
UA117480C2 (uk)	2013-04-03	2018-08-10	Санофі	Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
EP2991672A1 (en)	2013-04-30	2016-03-09	Novo Nordisk A/S	Novel administration regime
JP6438944B2 (ja) *	2013-06-17	2018-12-19	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	インスリングラルギン／リキシセナチド固定比率製剤
MX2016008979A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
MX2016008978A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
BR112016015851A2 (pt)	2014-01-09	2017-08-08	Sanofi Sa	Formulações farmacêuticas estabilizadas de insulina aspart
WO2015170286A2 (en) *	2014-05-08	2015-11-12	Biolingus Ip Llc	Modulation of blood glucose levels
EP3229828B1 (en) *	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
PT3229828T (pt) *	2015-11-10	2023-06-29	Sanofi Aventis Deutschland	Formulação de razão fixa de insulina glargina/lixisenatido
WO2018055539A1 (en) *	2016-09-22	2018-03-29	Wockhardt Limited	Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
CN117558435B (zh) *	2024-01-11	2024-03-19	四川省医学科学院·四川省人民医院	一种基于bcm设备的远程透析指导系统

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
PL1971362T3 (pl) *	2005-08-19	2015-05-29	Amylin Pharmaceuticals Llc	Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
DE102008053048A1 (de) *	2008-10-24	2010-04-29	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten

2010
- 2010-05-28 EP EP10164368A patent/EP2389945A1/en not_active Ceased
2011
- 2011-05-27 US US13/700,631 patent/US20130079279A1/en not_active Abandoned
- 2011-05-27 WO PCT/EP2011/058764 patent/WO2011147980A1/en not_active Ceased
- 2011-05-27 DK DK11723919.4T patent/DK2575865T3/en active
- 2011-05-27 PL PL11723919T patent/PL2575865T3/pl unknown
- 2011-05-27 AR ARP110101825A patent/AR081254A1/es unknown
- 2011-05-27 ES ES11723919.4T patent/ES2532994T3/es active Active
- 2011-05-27 EP EP14197154.9A patent/EP2898895A1/en not_active Ceased
- 2011-05-27 EP EP11723919.4A patent/EP2575865B1/en not_active Not-in-force
- 2011-05-27 HU HUE11723919A patent/HUE024486T2/en unknown
- 2011-05-27 EP EP17202727.8A patent/EP3300741A1/en not_active Withdrawn
- 2011-05-27 TW TW100118675A patent/TW201201832A/zh unknown

Also Published As

Publication number	Publication date
AR081254A1 (es)	2012-07-18
WO2011147980A1 (en)	2011-12-01
US20130079279A1 (en)	2013-03-28
DK2575865T3 (en)	2015-03-23
EP2575865B1 (en)	2014-12-17
EP2898895A1 (en)	2015-07-29
EP2389945A1 (en)	2011-11-30
ES2532994T3 (es)	2015-04-06
EP3300741A1 (en)	2018-04-04
TW201201832A (en)	2012-01-16
EP2575865A1 (en)	2013-04-10
HUE024486T2 (en)	2016-01-28

Publication	Publication Date	Title
PL2575865T3 (pl)	2015-06-30	Kompozycja farmaceutyczna obejmująca AVE0010 i insulinę glargine
IL253870B (en)	2018-05-31	Certain amino-pyrimidines and pharmaceutical preparations containing them
PL2583703T3 (pl)	2018-04-30	Samoniszcząca strzykawka insulinowa z wymienną igłą
EP2563338A4 (en)	2014-06-18	HIGH SHEAR APPLICATION USED FOR DRUG DELIVERY
ZA201406233B (en)	2015-11-25	Pharmaceutical composition and administration thereof
ZA201301419B (en)	2014-07-30	Pharmaceutical composition and administrations thereof
GB201003731D0 (en)	2010-04-21	Immediate/delayed drug delivery
EP2718317A4 (en)	2015-04-08	GLUCOSE-DEPENDENT INSULINOTROPE POLYPEPTIDE ANALOGUE, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
IL226297A0 (en)	2013-07-31	A pre-fillable syringe with dual chambers and pre-filled aripiprazole
SG10201601327RA (en)	2016-03-30	Glycosylated polypeptide and drug composition containing said polypeptide
PL2523666T3 (pl)	2016-06-30	Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-5-alfa-pregnan-20-on o ulepszonych właściwościach przechowywania i rozpuszczalności
EP2576612A4 (en)	2014-07-09	INSULIN ANALOG
EP2700654A4 (en)	2014-12-17	HUMAN INSULIN AND ANALOG CONJUGATE THEREOF
ZA201409508B (en)	2016-08-31	Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
EP2547384A4 (en)	2014-07-23	DEVICE FOR DELIVERY OF MEDICATION WITH GAS PRESSURE
EP2586324A4 (en)	2014-01-08	TRANSDERMAL ADMINISTRATION BRACELET
GB0906195D0 (en)	2009-05-20	Needle and syringe
IL223707A0 (en)	2013-03-05	N-hydroxyformamide derivative and medicament containing same
IL221501A (en)	2016-11-30	Medicinal product containing miramistine
EP2668958A4 (en)	2014-10-08	CASPOFUNGIN ANALOGS AND APPLICATIONS THEREOF
SG10201601324VA (en)	2016-03-30	Glycosylated polypeptide and drug composition containing said polypeptide
AP2788A (en)	2013-10-31	Simalikalactone E and use thereof as a medicament
GB201311029D0 (en)	2013-08-07	Pre-filled sing-use syringe
HRP20150125T1 (hr)	2015-03-27	Farmaceutski oblik koji sadrži aspirin i bisoprolol
GB201012660D0 (en)	2010-09-15	Inhaler and formulation